Guizhou Sanli PharmaceuticalLtd Past Earnings Performance
Past criteria checks 4/6
Guizhou Sanli PharmaceuticalLtd has been growing earnings at an average annual rate of 26%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 23.6% per year. Guizhou Sanli PharmaceuticalLtd's return on equity is 18.1%, and it has net margins of 15.6%.
Key information
26.0%
Earnings growth rate
24.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 23.6% |
| Return on equity | 18.1% |
| Net Margin | 15.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Guizhou Sanli PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,113 | 329 | 1,086 | 42 |
| 30 Jun 24 | 1,925 | 309 | 1,009 | 38 |
| 31 Mar 24 | 1,708 | 294 | 907 | 34 |
| 31 Dec 23 | 1,635 | 293 | 883 | 31 |
| 30 Sep 23 | 1,461 | 256 | 756 | 25 |
| 30 Jun 23 | 1,402 | 238 | 728 | 26 |
| 31 Mar 23 | 1,392 | 232 | 719 | 22 |
| 31 Dec 22 | 1,201 | 201 | 628 | 18 |
| 30 Sep 22 | 1,035 | 144 | 557 | 16 |
| 30 Jun 22 | 992 | 147 | 528 | 10 |
| 31 Mar 22 | 968 | 153 | 513 | 9 |
| 31 Dec 21 | 939 | 152 | 494 | 8 |
| 30 Sep 21 | 881 | 157 | 451 | 5 |
| 30 Jun 21 | 725 | 117 | 373 | 5 |
| 31 Mar 21 | 612 | 92 | 313 | 6 |
| 31 Dec 20 | 630 | 94 | 305 | 6 |
| 30 Sep 20 | 676 | 88 | 335 | 4 |
| 30 Jun 20 | 818 | 124 | 388 | 2 |
| 31 Mar 20 | 888 | 137 | 417 | 4 |
| 31 Dec 19 | 884 | 133 | 421 | 4 |
| 30 Jun 19 | 771 | 108 | 378 | 9 |
| 31 Mar 19 | 754 | 104 | 368 | 7 |
| 31 Dec 18 | 722 | 110 | 358 | 7 |
| 30 Jun 18 | 700 | 120 | 347 | 0 |
| 31 Mar 18 | 665 | 106 | 343 | 0 |
| 31 Dec 17 | 638 | 88 | 324 | 3 |
| 30 Sep 17 | 597 | 77 | 308 | 0 |
| 30 Jun 17 | 556 | 66 | 292 | 0 |
| 31 Mar 17 | 501 | 68 | 254 | 0 |
| 31 Dec 16 | 515 | 75 | 256 | 0 |
| 30 Sep 16 | 464 | 69 | 225 | 0 |
| 30 Jun 16 | 414 | 63 | 193 | 0 |
| 31 Mar 16 | 386 | 58 | 180 | 0 |
| 31 Dec 15 | 359 | 53 | 166 | 0 |
| 30 Sep 15 | 325 | 46 | 150 | 0 |
| 30 Jun 15 | 291 | 40 | 136 | 0 |
| 31 Mar 15 | 279 | 34 | 133 | 0 |
| 31 Dec 14 | 267 | 29 | 129 | 0 |
| 31 Dec 13 | 159 | 19 | 78 | 0 |
Quality Earnings: 603439 has high quality earnings.
Growing Profit Margin: 603439's current net profit margins (15.6%) are lower than last year (17.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603439's earnings have grown significantly by 26% per year over the past 5 years.
Accelerating Growth: 603439's earnings growth over the past year (28.7%) exceeds its 5-year average (26% per year).
Earnings vs Industry: 603439 earnings growth over the past year (28.7%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 603439's Return on Equity (18.1%) is considered low.